SCHEMBL2911447

SCHEMBL2911447

CO[C@H]1O[C@H](COC(=O)c2ccccc2)[C@@H](F)[C@H](OC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 11/20 0.47
USP2 O75604 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LGALS3 P17931 2/20 0.43
LGALS4 P56470 1/20 0.43
PTPN2 P17706 1/20 0.42
PTPN11 Q06124 1/20 0.42
F11 P03951 2/20 0.41
TMPRSS2 O15393 1/20 0.41
PDE5A O76074 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
HMGCR P04035 1/20 0.41
CYP1A2 P05177 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
HSPD1 P10809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12807944 1.00 PTPN1 (0.47) PTPN1USP2MEN1POLBKMT2A
SCHEMBL3452846 1.00 PTPN1 (0.47) PTPN1USP2MEN1POLBKMT2A
SCHEMBL10491974 0.96 PTPN1 (0.46) PTPN1USP2MEN1POLBKMT2A
SCHEMBL10491971 0.96 PTPN1 (0.46) PTPN1USP2MEN1POLBKMT2A
SCHEMBL20692018 0.96 PTPN1 (0.46) PTPN1USP2MEN1POLBKMT2A
SCHEMBL25084349 0.91 PTPN1 (0.56) PTPN1USP2MEN1POLBKMT2A
SCHEMBL13275617 0.91 PTPN1 (0.56) PTPN1USP2MEN1POLBKMT2A
SCHEMBL22983992 0.90 PTPN1 (0.57) PTPN1USP2MEN1POLBKMT2A
SCHEMBL11232105 0.90 PTPN1 (0.57) PTPN1USP2MEN1POLBKMT2A
SCHEMBL22984008 0.90 PTPN1 (0.57) PTPN1USP2MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267940-A1 Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative CENTRAL GLASS COMPANY, LIMITED (JP) 2010-10-21 US claimed
EP-2216337-A1 METHOD FOR PRODUCING 4-DEOXY-4-FLUORO-D-GLUCOSE DERIVATIVE Central Glass Company, Limited (JP) 2010-08-11 EP claimed
EP-2406270-B1 METHOD FOR MANUFACTURING 4-FLUORO-4-DESOXY-ALPHA-D-GLUCOPYRANOSIDES SANOFI SA (FR) 2013-04-17 EP disclosed
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SANOFI (FR) 2012-10-25 US disclosed
US-7820804-B2 Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof Sanofi-Aventia Deutschland GmbH (DE) 2010-10-26 US disclosed
US-20100267940-A1 Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative CENTRAL GLASS COMPANY, LIMITED (JP) 2010-10-21 US disclosed
US-20100261664-A1 Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-10-14 US disclosed
EP-2216337-A1 METHOD FOR PRODUCING 4-DEOXY-4-FLUORO-D-GLUCOSE DERIVATIVE Central Glass Company, Limited (JP) 2010-08-11 EP disclosed
WO-2010077623-A1 INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF FLUOROGLYCOSIDE DERIVATIVES SANOFI-AVENTIS (FR) 2010-07-08 WO disclosed
WO-2010066643-A1 METHOD FOR PRODUCING 4-FLUORO-4-DEOXY-ALPHA-D-GLUCOPYRANOSIDES SANOFI-AVENTIS (FR) 2010-06-17 WO disclosed
US-20080108580-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-05-08 US disclosed
EP-1572708-B1 NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2006-04-19 EP disclosed
EP-1572707-B1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2006-03-29 EP disclosed
WO-2005121161-A1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-12-22 WO disclosed
EP-1572707-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF Aventis Pharma Deutschland GmbH (DE) 2005-09-14 EP disclosed
EP-1572708-A1 NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF Aventis Pharma Deutschland GmbH (DE) 2005-09-14 EP disclosed
US-20050014704-A1 Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-20 US disclosed
US-20040259819-A1 Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-12-23 US disclosed
WO-2004052902-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-24 WO disclosed
WO-2004052903-A1 NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108580-A1 NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SLC5A2, SLC5A1, UGGT1 PTPN1 922/4885USP2 4363/4885MEN1 3350/4885
US-20100261664-A1 Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof UGGT1, SLC5A2, SLC5A1 PTPN1 1721/4885USP2 3915/4885MEN1 1285/4885
US-20100267940-A1 Method for Producing 4-Deoxy-4-Fluoro-D-Glucose Derivative SLC5A2, PFKFB3, PFKFB2 PTPN1 2814/4885USP2 4072/4885MEN1 2171/4885
US-20040259819-A1 Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof SLC5A1, UGGT1, SLC5A2 PTPN1 1654/4885USP2 3990/4885MEN1 1156/4885
US-20050014704-A1 Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof SLC5A2, SLC5A1, UGGT1 PTPN1 922/4885USP2 4363/4885MEN1 3350/4885
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SLC5A1, SLC5A2, SOST PTPN1 895/4885USP2 4333/4885MEN1 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.